论文部分内容阅读
目的:测定Graves’病患者131I治疗前后血清FT3、FT4、sTSH、TRAb、TGA、TMA含量,探讨变化规律及在诊断、治疗中的临床意义。方法:应用标记免疫分析法测定172例Graves’病患者131I治疗前、治疗后3、6、12和18个月及43例正常人血清FT3、FT4、sTSH、TRAb、TGA、TMA的含量。结果:与治疗前及正常人比较,治疗后3个月血清FT3、FT4含量明显降低,sTSH、TRAb含量明显升高。TGA、TMA值呈上升趋势。6个月FT3、FT4、sTSH含量接近对照组,TRAb呈下降趋势,TGA、TMA值明显升高。12个月TRAb、TGA、TMA值明显下降,18个月各项指标均接近正常。结论:动态观察Graves’病患者131I治疗前后FT3、FT4、sTSH、TRAb、TGA、TMA血清中含量的变化,对观察治疗疗效、指导治疗及预后均有重要意义。
OBJECTIVE: To determine the serum levels of FT3, FT4, sTSH, TRAb, TGA and TMA in patients with Graves’ disease before and after 131I treatment, and to explore the changing rules and their clinical significance in diagnosis and treatment. Methods: The contents of FT3, FT4, sTSH, TRAb, TGA and TMA in serum of 172 patients with Graves’ disease before 131I treatment, 3, 6, 12 and 18 months after treatment and 43 normal persons were measured by the method of labeled immunoassay. Results: Compared with pre-treatment and normal subjects, serum FT3 and FT4 levels were significantly decreased and sTSH and TRAb levels were significantly increased 3 months after treatment. TGA, TMA value is on the rise. At 6 months, the content of FT3, FT4 and sTSH was close to that of the control group, TRAb showed a decreasing trend and TGA and TMA values were significantly higher. The TRAb, TGA and TMA values decreased significantly at 12 months, and all the indexes at 18 months were close to normal. Conclusion: The dynamic changes of serum FT3, FT4, sTSH, TRAb, TGA and TMA in patients with Graves’ disease before and after 131I treatment are of great significance in observing the curative effect, guiding treatment and prognosis.